A new trading day began on Monday, with Relmada Therapeutics Inc (NASDAQ: RLMD) stock price up 5.94% from the previous day of trading, before settling in for the closing price of $0.37. RLMD’s price has ranged from $0.35 to $7.22 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 16.46%. With a float of $25.17 million, this company’s outstanding shares have now reached $30.17 million.
The firm has a total of 20 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Relmada Therapeutics Inc (RLMD) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Relmada Therapeutics Inc is 16.58%, while institutional ownership is 41.26%. The most recent insider transaction that took place on Sep 11 ’24, was worth 153,707. In this transaction Chief Executive Officer of this company bought 51,407 shares at a rate of $2.99, taking the stock ownership to the 384,024 shares. Before that another transaction happened on Sep 09 ’24, when Company’s Chief Executive Officer bought 55,579 for $2.71, making the entire transaction worth $150,619. This insider now owns 299,603 shares in total.
Relmada Therapeutics Inc (RLMD) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 16.46% per share during the next fiscal year.
Relmada Therapeutics Inc (NASDAQ: RLMD) Trading Performance Indicators
Here are Relmada Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.89.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.87, a number that is poised to hit -0.71 in the next quarter and is forecasted to reach -1.15 in one year’s time.
Technical Analysis of Relmada Therapeutics Inc (RLMD)
Analysing the last 5-days average volume posted by the [Relmada Therapeutics Inc, RLMD], we can find that recorded value of 1.69 million was better than the volume posted last year of 0.33 million. As of the previous 9 days, the stock’s Stochastic %D was 3.76%. Additionally, its Average True Range was 0.25.
During the past 100 days, Relmada Therapeutics Inc’s (RLMD) raw stochastic average was set at 1.05%, which indicates a significant decrease from 1.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 609.84% in the past 14 days, which was higher than the 255.53% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.7751, while its 200-day Moving Average is $3.4512. Now, the first resistance to watch is $0.4160. This is followed by the second major resistance level at $0.4431. The third major resistance level sits at $0.4738. If the price goes on to break the first support level at $0.3582, it is likely to go to the next support level at $0.3275. Now, if the price goes above the second support level, the third support stands at $0.3004.
Relmada Therapeutics Inc (NASDAQ: RLMD) Key Stats
With a market capitalization of 11.63 million, the company has a total of 30,174K Shares Outstanding. Currently, annual sales are 0 K while annual income is -98,790 K. The company’s previous quarter sales were 0 K while its latest quarter income was -21,730 K.
